| abstract |
The present application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]- 3,3'-diyl)bis(azanodiyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl ))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), which includes preparation processes thereof, where the solid forms and the Salt forms are useful for treating various diseases including infectious diseases and cancer. |